PTIE - Pain Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2400
+0.0800 (+6.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.1600
Open1.1900
Bid0.0000 x 800
Ask0.0000 x 3000
Day's Range1.1800 - 1.2699
52 Week Range0.7600 - 10.8000
Volume294,506
Avg. Volume244,900
Market Cap21.352M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatch2 months ago

    Pain Therapeutics to change name to Cassava Sciences and adopt ticker 'SAVA' fromThursday

    Pain Therapeutics Inc. said Wednesday it's changing its name and ticker to better reflect its focus on developing drugs for neurodegenerative diseases such as Alzheimer's. The company will be named Cassava Sciences Inc. with immediate effect. From March 28, it will start trading on Nasdaq under the new ticker symbol "SAVA." The company is currently in a phase 2 testing of a drug candidate aimed at treating Alzheimer's, that does not seek to clear amyloid from the brain, but rather to stabilize a critical protein in the brain. It is also working to develop a biomarker/diagnostic to detect Alzheimer's using a simple blood test. Shares rose 1.7% in premarket trade, but have fallen 82.2% in the last 12 months, while the S&P 500 has gained 7.9%.

  • Pain Therapeutics, Inc. (NASDAQ:PTIE): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.3 months ago

    Pain Therapeutics, Inc. (NASDAQ:PTIE): What Does Its Beta Value Mean For Your Portfolio?

    If you own shares in Pain Therapeutics, Inc. (NASDAQ:PTIE) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...

  • Market Exclusive4 months ago

    Market Update: May Back to Brussels, BP Gushes Oil, Iron Spike, Pain Feels Pain

    Back to Brussels, May Says No Support for Second Brexit Referendum British Prime Minister Theresa May, who somehow is still the Prime Minister of the United Kingdom despite being defeated in almost every critical legislative vote surrounding Brexit which she was brought aboard to deliver, is going back to Brussels to renegotiate the Irish backstop, […] The post Market Update: May Back to Brussels, BP Gushes Oil, Iron Spike, Pain Feels Pain appeared first on Market Exclusive.

  • Do Directors Own Pain Therapeutics Inc (NASDAQ:PTIE) Shares?
    Simply Wall St.6 months ago

    Do Directors Own Pain Therapeutics Inc (NASDAQ:PTIE) Shares?

    Every investor in Pain Therapeutics Inc (NASDAQ:PTIE) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • TheStreet.com8 months ago

    Pain Therapeutics Loses Half Its Value After Revealing Dispute With FDA

    shed 53% to $1.35 on Thursday, Oct. 4, after the company said it was filing an "administrative appeal" with the Federal Drug Administration after the agency rejected a drug the company was developing. In August, the FDA rejected Pain Therapeutics' Remoxy drug, an oxycodone designed to discourage most methods of tampering linked to opioid abuse, because the benefits of the drug weren't great enough to justify the risks. The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, part of the FDA, voted 14 to 3 against the drug.

  • 3 Drug/Biotech Stocks in Focus on World Alzheimer's Day
    Zacks8 months ago

    3 Drug/Biotech Stocks in Focus on World Alzheimer's Day

    We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.

  • Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
    Zacks9 months ago

    Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

    Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

  • Pain Therapeutics' Shares Rally on Alzheimer's Study Grant
    Zacks9 months ago

    Pain Therapeutics' Shares Rally on Alzheimer's Study Grant

    Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.

  • Pain Therapeutics Stock Skyrockets on Alzheimer’s Grant
    InvestorPlace9 months ago

    Pain Therapeutics Stock Skyrockets on Alzheimer’s Grant

    Pain Therapeutics notes that the grant is for a total of $3.20 million. PTI-125 is a new drug that Pain Therapeutics is developing to treat Alzheimer’s disease. The drug is a molecule that has the potential to treat Alzheimer’s disease.

  • Benzinga10 months ago

    FDA Decision Sends Pain Therapeutics Reeling

    The FDA rejected Pain’s lead asset and said the drug’s negatives outweigh its positives. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," Pain Therapeutics CEO Remi Barbier said in a statement. Pain Therapeutics said it will redirect its resources to advance its Alzheimer’s assets.

  • Reuters10 months ago

    U.S. FDA declines to approve Pain Therapeutics' abuse-deterrent opioid drug

    Pain Therapeutics said on Monday that the U.S. Food and Drug Administration declined to approve its opioid drug for the management of severe pain as the benefits of the drug did not outweigh the risk. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," said Chief Executive Officer Remi Barbier said in a statement. The FDA's "complete response letter" marks the latest setback to the U.S. drug developer and the treatment, Remoxy ER, which has failed to get marketing approval on the past three attempts.

  • Benzinga10 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

    Earnings is providing a much-needed boost to the biotech sector last week, with big-name companies like Eli Lilly And Co (NYSE: LLY ) and Pfizer Inc. (NYSE: PFE ) all trading at fresh 52-week highs in ...

  • Benzinga10 months ago

    Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

    Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is up about 5 percent. As the earnings season kicks ...

  • InvestorPlace11 months ago

    Remoxy’s Rejection Drives PTIE Stock 70% Lower

    This week was a rough one for biotech company Pain Therapeutics, Inc. (NASDAQ:PTIE) after the firm’s pain drug, Remoxy ER, was shot down by the FDA advisory committee. PTIE stock had been trading at more than $9 per share ahead of the news and investors were hopeful about the drug’s potential. The biotech space is a risky one because FDA approval weighs so heavily on companies’ success.

  • Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER
    Zacks11 months ago

    Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER

    Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.

  • Here's Why Drug Developer DURECT Corporation Plunged Today
    Motley Fool11 months ago

    Here's Why Drug Developer DURECT Corporation Plunged Today

    Remoxy is the gift that keeps on giving (and not in a good way).

  • Benzinga11 months ago

    Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...

  • Benzinga11 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

    Biotech stocks saw some upward momentum last week. The defensive nature of biotech stocks drove investors into the space amid a rise in risk aversion following the ongoing U.S.-China trade war. The week ...

  • Benzingalast year

    Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

    The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved ...